Abstract

BackgroundTreatment of Polymyalgia rheumatica (PMR) is subject to wide variations in clinical practice. We are currently developing new management guidelines for PMR for endorsement by ACR and EULAR.ObjectivesTo review the...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
SP0038 Review of the Key Evidence Supporting the New Treatment Guidelines in Polymyalgia Rheumatica
C Dejaco
Annals of the Rheumatic Diseases | VOL. 73
C DejacoC Dejaco
01 Jun 2014
The prevalences and levels of occupational exposure to dusts and/or fibres (silica, asbestos and coal): A systematic review and meta-analysis from the WHO/ILO Joint Estimates of the Work-related Burden of Disease and Injury
...
Environment International | VOL. 178
, et. al. ...
21 May 2023
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
Dennis A Eichenauer ... Jeremy Franklin
The Cochrane database of systematic reviews | VOL. 9
Dennis A Eichenauer, et. al.Dennis A Eichenauer ... Jeremy Franklin
13 Sep 2017
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia
Shuangnian Xu ... Jieping Chen
Cochrane Database of Systematic Reviews | VOL. -
Shuangnian Xu, et. al.Shuangnian Xu ... Jieping Chen
03 Jun 2015
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers